Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
65
TEVA Quote, Financials, Valuation and Earnings
Last price:
$33.96
Seasonality move
:
4.66%
Day range:
$33.92 - $34.80
52-week range:
$12.47 - $37.35
Dividend yield:
0%
P/E ratio:
28.16x
P/S ratio:
2.29x
P/B ratio:
5.05x
Volume:
5.5M
Avg. volume:
10.7M
1-year change:
106.81%
Market cap:
$40B
Revenue:
$17.5B
EPS (TTM):
$1.22
Analysts' Opinion
-
Consensus RatingTeva Pharmaceutical Industries Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $37.59, Teva Pharmaceutical Industries Ltd. has an estimated upside of 9.56% from its current price of $34.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $28.00 representing 18.39% downside risk from its current price of $34.31.
Fair Value
-
According to the consensus of 8 analysts, Teva Pharmaceutical Industries Ltd. has 9.56% upside to fair value with a price target of $37.59 per share.
TEVA vs. S&P 500
-
Over the past 5 trading days, Teva Pharmaceutical Industries Ltd. has underperformed the S&P 500 by -1.99% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Teva Pharmaceutical Industries Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Teva Pharmaceutical Industries Ltd. has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Teva Pharmaceutical Industries Ltd. reported revenues of $4.8B.
Earnings Growth
-
Teva Pharmaceutical Industries Ltd. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Teva Pharmaceutical Industries Ltd. reported earnings per share of $0.41.
Enterprise value:
53.6B
EV / Invested capital:
2.14x
Price / LTM sales:
2.29x
EV / EBIT:
13.41x
EV / Revenue:
3.08x
PEG ratio (5yr expected):
-0.09x
EV / Free cash flow:
53.39x
Price / Operating cash flow:
39.79x
Enterprise value / EBITDA:
10.70x
Gross Profit (TTM):
$9B
Return On Assets:
3.6%
Net Income Margin (TTM):
8.2%
Return On Equity:
20.99%
Return On Invested Capital:
5.9%
Operating Margin:
27.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $15.8B | $16.6B | $17.4B | $4.2B | $4.8B | |
| Gross Profit | $7.6B | $8.1B | $9B | $2.1B | $2.7B | |
| Operating Income | $3.2B | $3.4B | $4B | $894.1M | $1.3B | |
| EBITDA | $4.3B | $4.4B | $5B | $1.2B | $1.6B | |
| Diluted EPS | -$0.50 | -$1.45 | $1.22 | -$0.19 | $0.41 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.6B | $12.1B | $12.5B | $12.6B | $13.9B | |
| Total Assets | $47.7B | $44B | $43.5B | $39.3B | $40.7B | |
| Current Liabilities | $11B | $11.5B | $12.2B | $12.8B | $13.5B | |
| Total Liabilities | $36.4B | $35.4B | $35.4B | $33.6B | $32.8B | |
| Total Equity | $11.2B | $8.6B | $8.1B | $5.7B | $7.9B | |
| Total Debt | $23.4B | $21.5B | $20.1B | $18.1B | $17.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.8B | $2.5B | $1.5B | $915M | $1.7B | |
| Cash From Investing | -$504.2M | -$563M | -$519.1M | -$138M | -$118.2M | |
| Cash From Financing | -$1.9B | -$1.7B | -$2.1B | -$674M | $38.7M | |
| Free Cash Flow | $2.3B | $2B | $1B | $786M | $1.5B | |
TEVA
Sector
Market Cap
$40B
$23.4M
Price % of 52-Week High
91.87%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
1.16%
-1.64%
1-Year Price Total Return
106.81%
-21.81%
Beta (5-Year)
0.702
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$34.92
200-day SMA
Buy
Level
$21.86
Bollinger Bands (100)
Buy
Level
20.91 - 32.13
Chaikin Money Flow
Buy
Level
10.5M
20-day SMA
Buy
Level
$33.37
Relative Strength Index (RSI14)
Buy
Level
61.50
ADX Line
Buy
Level
26.42
Williams %R
Neutral
Level
-47.3849
50-day SMA
Buy
Level
$31.60
MACD (12, 26)
Buy
Level
9.61
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
9.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9538)
Sell
CA Score
(Annual)
Level (-1.3724)
Buy
Beneish M-Score
(Annual)
Level (-2.494)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.4042)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Stock Forecast FAQ
In the current month, TEVA has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TEVA average analyst price target in the past 3 months is $37.59.
-
Where Will Teva Pharmaceutical Industries Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Teva Pharmaceutical Industries Ltd. share price will rise to $37.59 per share over the next 12 months.
-
What Do Analysts Say About Teva Pharmaceutical Industries Ltd.?
Analysts are divided on their view about Teva Pharmaceutical Industries Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Teva Pharmaceutical Industries Ltd. is a Sell and believe this share price will drop from its current level to $28.00.
-
What Is Teva Pharmaceutical Industries Ltd.'s Price Target?
The price target for Teva Pharmaceutical Industries Ltd. over the next 1-year time period is forecast to be $37.59 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TEVA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Teva Pharmaceutical Industries Ltd. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TEVA?
You can purchase shares of Teva Pharmaceutical Industries Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Teva Pharmaceutical Industries Ltd. shares.
-
What Is The Teva Pharmaceutical Industries Ltd. Share Price Today?
Teva Pharmaceutical Industries Ltd. was last trading at $33.96 per share. This represents the most recent stock quote for Teva Pharmaceutical Industries Ltd.. Yesterday, Teva Pharmaceutical Industries Ltd. closed at $34.31 per share.
-
How To Buy Teva Pharmaceutical Industries Ltd. Stock Online?
In order to purchase Teva Pharmaceutical Industries Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get TEVA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TEVA
Sector
P/E ratio
28.16x
23.34x
PEG ratio
-0.09x
-0.01x
P/B ratio
5.05x
1.72x
Price / LTM sales
2.29x
1.51x
Growth Metrics
TEVA
Sector
Revenue growth
12.42%
3.21%
Earnings growth
313.26%
10.12%
Revenue (5-year growth)
0.94%
6.27%
Earnings forecast
$0.64
-$0.19
Profitability
TEVA
Sector
Profitability FY 2025
$9.1B
$2.7M
Return on invested capital
5.9%
-33.62%
Return on assets
3.6%
-29.68%
Return on equity
20.99%
-38.89%
Earnings Date
Last Earnings Date
Jan
28
Next Earnings Date
May
6
Estimated Next Earnings Date
Apr
29
Balance Sheet
TEVA
Sector
Total cash
$3.6B
$25M
Short term investments
--
$23.9M
Total assets
$40.7B
$72.8M
Long term debt
$17.1B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
